Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
1994-7-7
|
pubmed:abstractText |
Ninety-one patients with de novo acute myeloid leukemia (AML) in first complete remission (CR) undergoing an HLA-identical sibling BMT and with a minimum follow-up of 12 months were analyzed for disease-related and transplant-related variables predicting survival and relapse. The overall actuarial 5 year survival is 53% and the relapse rate 29%, with a medium follow-up for surviving patients of 1552 days (range 365-4094 days). In univariate analysis the following variables were found to be associated with an increased risk of failure: high-dose cyclosporin (CsA), M4-M6 FAB subtype and a long interval (> or = 180 days) between diagnosis and BMT. Other disease-related variables at presentation were not significant, including WBC count > 50 x 10(9)/l, marrow blasts < 70%, time to enter remission > 40 days and > 2 courses to enter remission. Survival was 58% vs 43% for M1-M3 vs M4-M6 FAB subtypes (p = 0.03) and 71% vs 42% for low-dose vs high-dose CsA (p = 0.01). A multivariate analysis was then run separately on survival, relapse and transplant related mortality (TRM). Survival was negatively influenced by M4-M6 FAB subtypes (p = 0.009), high-dose CsA (p = 0.03) and a long interval between diagnosis and BMT (p = 0.04). Leukemia relapse was higher in patients receiving high-dose CsA (p = 0.003) and in females (p = 0.04). Transplant-related mortality was higher in FAB M4-M6 patients (p = 0.01) and patients grafted late after diagnosis (p = 0.03).(ABSTRACT TRUNCATED AT 250 WORDS)
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Mar
|
pubmed:issn |
0268-3369
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
13
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
N
|
pubmed:pagination |
247-52
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:8199567-Acute Disease,
pubmed-meshheading:8199567-Adolescent,
pubmed-meshheading:8199567-Adult,
pubmed-meshheading:8199567-Bone Marrow Transplantation,
pubmed-meshheading:8199567-Child,
pubmed-meshheading:8199567-Child, Preschool,
pubmed-meshheading:8199567-Cyclosporine,
pubmed-meshheading:8199567-Dose-Response Relationship, Drug,
pubmed-meshheading:8199567-Female,
pubmed-meshheading:8199567-Graft vs Host Disease,
pubmed-meshheading:8199567-Humans,
pubmed-meshheading:8199567-Infant,
pubmed-meshheading:8199567-Leukemia, Myeloid,
pubmed-meshheading:8199567-Male,
pubmed-meshheading:8199567-Multivariate Analysis,
pubmed-meshheading:8199567-Recurrence,
pubmed-meshheading:8199567-Remission Induction,
pubmed-meshheading:8199567-Retrospective Studies,
pubmed-meshheading:8199567-Survival Rate,
pubmed-meshheading:8199567-Time Factors,
pubmed-meshheading:8199567-Transplantation, Homologous
|
pubmed:year |
1994
|
pubmed:articleTitle |
Allogeneic bone marrow transplantation for acute myeloid leukemia in first complete remission: the effect of FAB classification and GVHD prophylaxis.
|
pubmed:affiliation |
Divisione Ematologia 2, Ospedale San Martino, Genova, Italy.
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't
|